Novartis – AfricaNewsAnalysis

300 million child-friendly antimalarial treatments supplied without profit by Novartis

09/12/2015 ANA 0

Novartis (NVS) (http://www.Novartis.com) announced today that it has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 […]

Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries

29/09/2015 ANA 0

First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer Novartis portfolio to be offered to governments and non-governmental organizations in […]

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

24/04/2014 ANA 0

Novartis announced today (April 22, 2012) that it has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company’s portfolio. Under the agreement, Novartis […]

Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU

24/01/2014 ANA 0

Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure by the Committee for Medicinal Products for Human […]

Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch

24/01/2014 ANA 0

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for […]

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia

08/12/2013 ANA 0

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019. Several studies being presented at the […]

Novartis Africa Day unterstreicht die Bemühungen des Unternehmens für einen besseren Zugang zur Gesundheitsversorgung

05/12/2013 ANA 0

Heute treffen sich Führungsverantwortliche von Novartis in Basel, Schweiz, für den ersten Novartis Africa Day. Sie werden dort die innovative Arbeit des Unternehmens in Afrika prüfen, insbesondere die wachsenden kommerziellen Aktivitäten, neuartige Ansätze für einen […]

Novartis Africa Day highlights company’s efforts to expand access to healthcare

05/12/2013 ANA 0

Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, […]

New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

28/11/2013 ANA 0

Novartis scientists have discovered a new drug target for treating malaria. The discovery, which is published online in the journal Nature,[2] identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental antimalarial […]

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

07/10/2013 ANA 0

Novartis recently announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in patients with relapsing forms of multiple sclerosis (MS), and was associated with a higher […]

1 2 3 … 5 »